The use of Backscattering Interferometry to Investigate Positive Allosteric Modulators of the M4 Receptor
Presented by Dr. Jonathan Ellery, Principal Scientist, Takeda Cambridge, Ltd.
Presented on 3-September-2014, at the ELRIG Drug Discovery 2014 conference in Manchester, UK.
Evidence suggests that the activation of the muscarinic acetycholine receptors (mAChRs) in the central nervous system (CNS) may have therapeutic benefit in the treatment of a number of CNS disorders. The use of non-selective agonists is limited due to un-desirable peripheral side effects. One approach to overcome this issue is to identify compounds that selectively positively modulate the M4 mAChR subtype via an allosteric binding site. Here we describe the use of backscattering interferometry, a label free assay technology, to investigating the nature of modulator binding and its co-operative effects upon the binding of the natural ligand acetylcholine to the M4 mAChR.
About the Presenter
Dr. Jonathan Ellery is a principal scientist with 14 years of industrial experience working in the field of in vitro pharmacology. He has a keen interest in understanding how compounds engage with targets and seeks new methodologies and technologies that will further help in our understanding of this fundamental aspect of drug discovery.
FILL OUT THIS SHORT REGISTRATION FORM TO VIEW THE PRESENTATION NOW